成人4级弥漫性胶质瘤长复发间隔的整合纵向分析揭示复发肿瘤中TGF-β信号上调
单中心回顾性研究对复发间隔大于1年的初发与治疗后胶质瘤配对样本行全外显子测序联合mRNA和microRNA表达谱分析,发现75%患者复发肿瘤呈早期分支演化,复发肿瘤中ALK7/ACVR1C与LTBP1上调、LEFTY2下调,提示TGF-β信号增强,SBS1减少、SBS11升高反映烷化剂治疗影响。
要点
- 复发胶质瘤中75%患者呈早期分支演化,mRNA和microRNA水平证实高可塑性
- 复发肿瘤ALK7/ACVR1C与LTBP1上调、LEFTY2下调,提示TGF-β信号增强
- SBS1减少、SBS11升高,体现烷化剂治疗对突变图谱的影响
核心结论
- 结果提示TGF-β信号在复发胶质瘤中起重要作用,TGF-β抑制剂已进入临床期研究,可能用于联合治疗以干预放化疗耐药。
- 复发胶质瘤早期分支演化发生率高,肿瘤高可塑性在microRNA和mRNA表达谱水平得到证实。
研究设计与样本
- 单中心回顾性研究,纳入初发与治疗后配对、复发间隔大于1年的胶质瘤病例,行全外显子测序联合mRNA和microRNA表达谱分析。
主要发现
- 复发胶质瘤突变分析显示75%的患者存在早期分支演化。
- SBS1特征减少、SBS11升高,显示烷化剂治疗对突变图谱的影响。
- 无证据表明存在驱动治疗耐药的继发性基因组改变。
- ALK7/ACVR1C和LTBP1上调、LEFTY2下调,指向复发胶质瘤中TGF-β信号增强。
- microRNA表达谱改变指向核因子κB和Wnt信号增强,与TGF-β协同诱导上皮间质转化、迁移和干性;复发肿瘤中TGF-β诱导的促凋亡蛋白表达与抗凋亡蛋白抑制发生解偶联。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adult-type diffuse gliomas, CNS WHO grade 4 are the most aggressive primary brain tumors and represent a particular challenge for therapeutic intervention. METHODS: In a single-center retrospective study of matched pairs of initial and post-therapeutic glioma cases with a recurrence period greater than 1 year, we performed whole exome sequencing combined with mRNA and microRNA expression profiling to identify processes that are altered in recurrent gliomas. RESULTS: Mutational analysis of recurrent gliomas revealed early branching evolution in 75% of the patients. High plasticity was confirmed at the mRNA and miRNA levels. SBS1 signature was reduced and SBS11 was elevated, demonstrating the effect of alkylating agent therapy on the mutational landscape. There was no evidence for secondary genomic alterations driving therapy resistance. ALK7/ACVR1C and LTBP1 were upregulated, whereas LEFTY2 was downregulated, pointing towards enhanced Tumor Growth Factor β (TGF-β) signaling in recurrent gliomas. Consistently, altered microRNA expression profiles pointed towards enhanced Nuclear Factor Kappa B and Wnt signaling that, cooperatively with TGF-β, induces epithelial to mesenchymal transition (EMT), migration, and stemness. TGF-β-induced expression of pro-apoptotic proteins and repression of antiapoptotic proteins were uncoupled in the recurrent tumor. CONCLUSIONS: Our results suggest an important role of TGF-β signaling in recurrent gliomas. This may have clinical implications since TGF-β inhibitors have entered clinical phase studies and may potentially be used in combination therapy to interfere with chemoradiation resistance. Recurrent gliomas show high incidence of early branching evolution. High tumor plasticity is confirmed at the level of microRNA and mRNA expression profiles.
引用
- Kashani E, Schnidrig D, Gheinani AH, et al. Integrated longitudinal analysis of adult grade 4 diffuse gliomas with long-term relapse interval revealed upregulation of TGF-β signaling in recurrent tumors. Neuro Oncol. 2023. PMID: 36124685. doi:10.1093/neuonc/noac220
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。